JP2007536910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536910A5 JP2007536910A5 JP2006546329A JP2006546329A JP2007536910A5 JP 2007536910 A5 JP2007536910 A5 JP 2007536910A5 JP 2006546329 A JP2006546329 A JP 2006546329A JP 2006546329 A JP2006546329 A JP 2006546329A JP 2007536910 A5 JP2007536910 A5 JP 2007536910A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- derivative
- analogue
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000004475 Arginine Substances 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- 101710095342 Apolipoprotein B Proteins 0.000 claims 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108090000054 Syndecan-2 Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0329958.3A GB0329958D0 (en) | 2003-12-24 | 2003-12-24 | Treatment of viral infections |
| PCT/GB2004/005438 WO2005061539A2 (en) | 2003-12-24 | 2004-12-20 | Treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007536910A JP2007536910A (ja) | 2007-12-20 |
| JP2007536910A5 true JP2007536910A5 (enExample) | 2008-02-07 |
Family
ID=30776474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006546329A Pending JP2007536910A (ja) | 2003-12-24 | 2004-12-20 | ウイルス感染の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8017579B2 (enExample) |
| EP (1) | EP1711526B1 (enExample) |
| JP (1) | JP2007536910A (enExample) |
| CA (1) | CA2548740A1 (enExample) |
| GB (1) | GB0329958D0 (enExample) |
| WO (1) | WO2005061539A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781219B2 (en) | 2003-12-05 | 2010-08-24 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| GB0404374D0 (en) * | 2004-02-27 | 2004-03-31 | Univ Manchester | Treatment of bacterial infections |
| US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
| CN101065479A (zh) | 2004-10-15 | 2007-10-31 | 蒙奈尔化学感觉中心 | 培养哺乳动物味细胞的方法 |
| GB0513096D0 (en) * | 2005-06-28 | 2005-08-03 | Strathclyde | Treatment of microbial infections |
| AU2006291990B2 (en) | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| CA2776513C (en) | 2009-11-24 | 2017-08-01 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| US9234026B2 (en) | 2011-07-21 | 2016-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Apolipoprotein E polypeptides and their use |
| MX2014010164A (es) | 2012-02-22 | 2014-11-25 | Alethia Biotherapeutics Inc | Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer. |
| MY151307A (en) * | 2012-06-18 | 2014-05-05 | Univ Malaya | Peptides having antimicrobial activity |
| CN117547596A (zh) * | 2023-11-20 | 2024-02-13 | 吉林越洋血浆蛋白研究院有限责任公司 | 人血载脂蛋白a1制品在制备抗包膜病毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340727A (en) | 1987-11-17 | 1994-08-23 | The Scripps Research Institute | GPIbα fragments and recombinant DNA expression vectors |
| US5344822A (en) | 1992-08-12 | 1994-09-06 | The Rogosin Institute | Methods useful in endotoxin prophylaxis and therapy |
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| GB9620153D0 (en) * | 1996-09-27 | 1996-11-13 | Univ Strathclyde | Non-naturally occurring lipoprotein particle |
| GB9705831D0 (en) * | 1997-03-20 | 1997-05-07 | Univ Leicester | Oxidised ldl |
| ATE349225T1 (de) | 1997-11-06 | 2007-01-15 | Innogenetics Nv | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv |
| AU760794B2 (en) * | 1998-03-10 | 2003-05-22 | Regents Of The University Of California, The | Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding |
| US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US20040014955A1 (en) | 2001-12-17 | 2004-01-22 | Carlos Zamudio | Identification of essential genes of cryptococcus neoformans and methods of use |
| US20050208078A1 (en) * | 2003-11-20 | 2005-09-22 | Hoffman Stephen L | Methods for the prevention of malaria |
| AU2004283078A1 (en) | 2003-10-01 | 2005-05-06 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| GB0329254D0 (en) * | 2003-12-17 | 2004-01-21 | Univ Manchester | Treatment of viral infections |
| GB0404374D0 (en) | 2004-02-27 | 2004-03-31 | Univ Manchester | Treatment of bacterial infections |
| GB0513096D0 (en) | 2005-06-28 | 2005-08-03 | Strathclyde | Treatment of microbial infections |
-
2003
- 2003-12-24 GB GBGB0329958.3A patent/GB0329958D0/en not_active Ceased
-
2004
- 2004-12-20 EP EP04806232A patent/EP1711526B1/en not_active Expired - Lifetime
- 2004-12-20 US US10/580,984 patent/US8017579B2/en not_active Expired - Fee Related
- 2004-12-20 CA CA002548740A patent/CA2548740A1/en not_active Abandoned
- 2004-12-20 WO PCT/GB2004/005438 patent/WO2005061539A2/en not_active Ceased
- 2004-12-20 JP JP2006546329A patent/JP2007536910A/ja active Pending